Comparison of Two Dosages of Barisitinib for Rheumatoid Arthritis Treatment

The chapter evaluates the efficacy and safety of 2mg and 4mg dosages of barisitinib for treating moderate to severe rheumatoid arthritis, highlighting higher rates of low disease activity and remission with the 4mg dosage. Safety data including cases of herpes zoster, skin eruptions, renal impairment, and dosage recommendations for elderly patients are also discussed.